Literature DB >> 25048722

CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma.

Huimin Shen1, Muyan Cai, Shanshan Zhao, Huan Wang, Mengxiong Li, Shuzhong Yao, Nan Jiang.   

Abstract

Cysteine-rich 61 (CYR61) has been proven to be an oncogene with potential predictive and prognostic implications in a variety of human cancers. However, the expression pattern of CYR61 and its role in ovarian carcinoma remains largely unknown. In this study, the mRNA and protein levels of CYR61 in normal ovaries and ovarian carcinoma tissues were evaluated using reverse transcription-polymerase chain reaction, immunohistochemistry, and Western blotting. Compared to normal ovarian tissues, the mRNA and protein levels of CYR61 were significantly higher in ovarian carcinoma tissues. Moreover, receiver operating characteristic (ROC) curve analysis, Spearman's rank correlation, Kaplan-Meier plots, and the Cox proportional hazards regression model were used to investigate the potential association of the CYR61 protein with the development of ovarian carcinoma in an ovarian carcinoma cohort. Based on ROC curve analysis, high expression of CYR61 was defined as a tumor in which more than 70 % of cells were positively stained. Based on this cutoff value, high expression of CYR61 was detected in 51.5 % of invasive carcinomas, 35.3 % of borderline tumors, 25.9 % of cystadenomas, and 20 % in the normal ovaries. In ovarian carcinomas, CYR61 overexpression was associated with advanced FIGO stage. Univariate survival analysis on the ovarian carcinoma cohorts showed that overexpression of CYR61 was associated with poor survival of ovarian cancer patients. Multivariate analysis suggested that the protein level of CYR61 was an independent and significant prognostic factor for ovarian carcinoma. Our results suggest that the CYR61 protein is an important and independent biomarker for prognostic implications of ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048722     DOI: 10.1007/s12032-014-0117-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  40 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  The CCN family proteins in carcinogenesis.

Authors:  A Dhar; A Ray
Journal:  Exp Oncol       Date:  2010-03

Review 3.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3.

Authors:  M L Kireeva; S C Lam; L F Lau
Journal:  J Biol Chem       Date:  1998-01-30       Impact factor: 5.157

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 6.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

Authors:  W Glenn McCluggage
Journal:  Pathology       Date:  2011-08       Impact factor: 5.306

7.  High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma.

Authors:  Yong Li; Hao-Xian Yang; Rong-Zhen Luo; Ying Zhang; Mei Li; Xin Wang; Wei-Hua Jia
Journal:  Ann Thorac Surg       Date:  2011-05       Impact factor: 4.330

Review 8.  Functions and mechanisms of action of CCN matricellular proteins.

Authors:  Chih-Chiun Chen; Lester F Lau
Journal:  Int J Biochem Cell Biol       Date:  2008-08-15       Impact factor: 5.085

Review 9.  Histological classification of ovarian cancer.

Authors:  Tsunehisa Kaku; Shinji Ogawa; Yoshiaki Kawano; Yoshihiro Ohishi; Hiroaki Kobayashi; Toshio Hirakawa; Hitoo Nakano
Journal:  Med Electron Microsc       Date:  2003-03

10.  Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells.

Authors:  L F Lau; D Nathans
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more
  10 in total

1.  The Anti-Tumor Efficacy of Verbascoside on Ovarian Cancer via Facilitating CCN1-AKT/NF-κB Pathway-Mediated M1 Macrophage Polarization.

Authors:  Yu Ren; Jinying He; Wenhua Zhao; Yuzhen Ma
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

2.  Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.

Authors:  Xiaoyan Ren; Yifei Liu; Yumei Tao; Guoxiang Zhu; Meilan Pei; Jianguo Zhang; Jian Liu
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

3.  CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma.

Authors:  Jing Wei; Guanzhen Yu; Genbao Shao; Aiqin Sun; Miao Chen; Wannian Yang; Qiong Lin
Journal:  Oncotarget       Date:  2016-05-24

4.  CYR61 and TAZ Upregulation and Focal Epithelial to Mesenchymal Transition May Be Early Predictors of Barrett's Esophagus Malignant Progression.

Authors:  Joana Cardoso; Marta Mesquita; António Dias Pereira; Mónica Bettencourt-Dias; Paula Chaves; José B Pereira-Leal
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

5.  PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.

Authors:  Y Wang; V Justilien; K I Brennan; L Jamieson; N R Murray; A P Fields
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

6.  The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.

Authors:  Abel Matondo; Yong Hwa Jo; Muhammad Shahid; Tae Gyu Choi; Minh Nam Nguyen; Ngoc Ngo Yen Nguyen; Salima Akter; Insug Kang; Joohun Ha; Chi Hoon Maeng; Si-Young Kim; Ju-Seog Lee; Jayoung Kim; Sung Soo Kim
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

7.  FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Authors:  Renata A Tassi; Paola Todeschini; Eric R Siegel; Stefano Calza; Paolo Cappella; Laura Ardighieri; Moris Cadei; Mattia Bugatti; Chiara Romani; Elisabetta Bandiera; Laura Zanotti; Laura Tassone; Donatella Guarino; Concetta Santonocito; Ettore D Capoluongo; Luca Beltrame; Eugenio Erba; Sergio Marchini; Maurizio D'Incalci; Carla Donzelli; Alessandro D Santin; Sergio Pecorelli; Enrico Sartori; Eliana Bignotti; Franco Odicino; Antonella Ravaggi
Journal:  J Exp Clin Cancer Res       Date:  2017-05-08

8.  Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.

Authors:  Fengli Zhang; Huixiao Chen; Jing Du; Bin Wang; Lixiao Yang
Journal:  Med Sci Monit       Date:  2018-09-01

9.  Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer.

Authors:  Aeman Zahra; Qiduo Dong; Marcia Hall; Jeyarooban Jeyaneethi; Elisabete Silva; Emmanouil Karteris; Cristina Sisu
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

10.  Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.

Authors:  Ling-Yu Chu; Jian-Yuan Zhou; Yi-Xuan Zhao; Yan-Ting Ou; Tian Yang; Yu-Hui Peng; Wang-Kai Fang; Yi-Wei Xu; Jian-Jun Xie
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.